Fennec Pharmaceuticals (NASDAQ:FENC) posted its quarterly earnings data on Thursday. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.01, MarketWatch Earnings reports.
Shares of NASDAQ:FENC traded down $0.11 during trading on Friday, hitting $4.17. 101,870 shares of the company’s stock were exchanged, compared to its average volume of 81,854. Fennec Pharmaceuticals has a 1-year low of $4.09 and a 1-year high of $12.51.
Separately, Wedbush reiterated an “outperform” rating and set a $16.00 price target on shares of Fennec Pharmaceuticals in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $15.00.
An institutional investor recently raised its position in Fennec Pharmaceuticals stock. Geode Capital Management LLC lifted its holdings in shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) by 16.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,489 shares of the company’s stock after buying an additional 5,441 shares during the quarter. Geode Capital Management LLC owned about 0.20% of Fennec Pharmaceuticals worth $251,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 48.99% of the company’s stock.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Article: Oversold
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.